Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer.
Radioimmunoscintigraphy (RIS) with technetium-99m labelled SM3, a monoclonal antibody reacting with a polymorphic epithelial mucin glycoprotein core antigen, is evaluated. No adverse effects or thyroid uptake were observed. Studies in 45 patients (one twice) had a sensitivity for gynaecological malignancy of 100% (35/35) and a specificity of 73% (8/11), giving an overall accuracy of 93% (43/46). These results have led to the routine adoption of 99mTc RIS in the management of patients suspected of or having primary or recurrent gynaecological cancer.
Granowska
M
M
Nuclear Medicine Department, St. Bartholomew's Hospital, West Smithfield, London, UK.
Britton
K E
KE
Mather
S J
SJ
Lowe
D G
DG
Ellison
D
D
Bomanji
J
J
Burchell
J
J
Taylor-Papadimitriou
J
J
Hudson
C R
CR
Shepherd
J H
JH
D000328:Adult; D000368:Aged; D003536:Cystadenocarcinoma / Q000000981:diagnostic imaging; D005260:Female; D005833:Genital Neoplasms, Female / Q000000981:diagnostic imaging*; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging; D016719:Radioimmunodetection; D012680:Sensitivity and Specificity; D013667:Technetium
D013667:Technetium